CoA-LOT: BNBN20251114/CA
While localized injection site reactions such as mild erythema or swelling are common, systemic adverse events are rare at standard dosages when administered correctly
Metabolism & Elimination Limited characterization of specific metabolic pathways has been published for both peptides: CJC-1295 (NO DAC): Peptidase-mediated degradation represents primary metabolic pathway Four amino acid substitutions provide enhanced resistance to dipeptidyl peptidase-IV Metabolites and degradation products not fully characterized in published literature Clearance from circulation within hours despite sustained pharmacodynamic effects Ipamorelin: Clearance of 0.078 L/h/kg in human pharmacokinetic studies Rapid elimination from plasma following distribution phase Metabolic pathways likely involve proteolytic cleavage at peptide bonds No significant accumulation observed with repeated dosing in animal models A notable pharmacokinetic-pharmacodynamic disconnect exists: despite relatively short plasma half-lives (30 minutes to 2 hours), growth hormone secretory effects persist for 6+ hours, suggesting either active metabolites, tissue retention, or persistent receptor signaling cascade activation
Medication, Prescription Drug, and Topical Product Interactions Topical GHK-Cu may interact practically with other skin products by increasing irritation risk, especially in people using retinoids, acids, exfoliants, medicated creams, or post-procedure regimens
The Myers' Cocktail is a popular IV therapy that delivers a powerful dose of nutrients right into the bloodstream
View the COA on this page Use the size selector in the product form above to choose your preferred quantity
